Last reviewed · How we verify
Latanoprost ophthalmic solution 0.005%
At a glance
| Generic name | Latanoprost ophthalmic solution 0.005% |
|---|---|
| Also known as | Latanoprost, Xalatan®, latanoprost |
| Sponsor | Aerie Pharmaceuticals |
| Drug class | Prostaglandin Analog [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Conjunctival hyperemia
- Eye irritation
- Eye pruritus
- Abnormal sensation in eye
- Foreign body sensation in eyes
- Vision blurred
- Lacrimation increased
- Photophobia
Serious adverse events
- Macular edema, including cystoid macular edema
- Intraocular inflammation (iritis/uveitis)
- Corneal edema and erosions
- Pseudopemphigoid of the ocular conjunctiva
- Toxic epidermal necrolysis
- Asthma and exacerbation of asthma
- Herpes keratitis
- Angina unstable
- Keratitis
- Trichiasis
Key clinical trials
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients (PHASE4)
- Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension (PHASE2, PHASE3)
- Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment
- Rocklatan vs Latanoprost Post-DSLT (PHASE4)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- Optic Nerve Head Strain in Non-glaucoma Subjects (EARLY_PHASE1)
- Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (PHASE3)
- Next Generation Rocklatan (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Latanoprost ophthalmic solution 0.005% CI brief — competitive landscape report
- Latanoprost ophthalmic solution 0.005% updates RSS · CI watch RSS
- Aerie Pharmaceuticals portfolio CI